Table 2.
Specific patient's characteristics concerning diabetic foot ulcers, anti-diabetic medications and results of WF10 treatment
| Characteristics | Range | Average ± SD | NT | PP | AS | KP | NP | UA | PS | CW | SR | SA | NY | WW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DFS treatment outcome | ||||||||||||||
| Wagner score at week 0 | 1–4 | 4 | 3 | 4 | 4 | 3 | 3 | 3 | 1 | 3 | 3 | 3 | 3 | |
| Wagner score at week 12 | 0–2 | NA | 0 | 2 | 2 | 0 | 0 | 1 | 0 | 1 | NA | 0 | 0 | |
| Time to heal (week) | 1–28 | 11 ± 8 | – | 14 | – | 28 | 1 | 4 | – | 6 | 14 | – | 10 | 10 |
| Hemoglobin A1c (%) | ||||||||||||||
| At week 0 before WF10 | 9.7 | 9.2 | 11.5 | 8.9 | 7.7 | 6.9 | 11.1 | 9.8 | 7.7 | 8.4 | 11.0 | 7.1 | ||
| At week 4 | 5.5 | 7.8 | 4.8 | 6.2 | 6.5 | 5.1 | 6.8 | 7.4 | 8.4 | 5.4 | 9.5 | 6.7 | ||
| At week 8 | 5.3 | 5.4 | 6.4 | 5.2 | 5.1 | 5.5 | 7.0 | 8.7 | 6.9 | 6.1 | ||||
| At week 12 | 8.4 | 5.9 | 6.4 | 6.2 | 6.1 | 6.1 | 8.4 | 7.3 | 6.5 | |||||
| At week 16 | 6.2 | 7.4 | 8.2 | 5.9 | 6.4 | 10.1 | 6.9 | |||||||
| Blood Tx (unit) before WF10 Rx | 2 | – | – | – | 2 | – | – | – | – | 3 | – | – | ||
| Blood Tx (unit) during WF10 Rx | 8 | – | 4 | 4 | - | 2 | – | – | – | – | – | – | ||
| Previous anti-DM medication | ||||||||||||||
| Oral anti-diabetic | N | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | ||
| Previous insulin treatment (n) | Y | Y | N | N | N | N | N | Y | N | N | N | Y | ||
| Total dose insulin (U/day) | 10 | 50 | – | – | – | – | – | 35 | – | – | – | – | ||
| Anti-DM medication during treatment | ||||||||||||||
| Oral anti-diabetic | N | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | ||
| Insulin treatment (n) | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | ||
| Total dose insulin (U/day) | 10 | 50 | 30 | 15 | 10 | 6 | 10 | 35 | 4 | 6 | 3 | 62 |
Y, yes; N, no; NA, not analyzed.